Skip to main content Skip to footer
Novakand Pharma
  • Home
  • About us
    • Our Business
    • Strategy and business model
    • Management
    • Board of Directors
    • Contact us
  • Pipeline
    • Our Science
    • Pipeline overview
    • Projects
      • Rugocrixan
      • Fosrugocrixan
    • Business Development
    • IP
    • Publications
  • Therapeutic areas
    • Myocardial infarction
    • Ovarian cancer
  • Investors
    • Presentations
    • Press Releases
    • Financial Reports
    • Financial Calendar
    • Events
    • The Share
    • Sustainability
    • Corporate Governance
      • Articles of Association
      • Annual General Meeting
      • Board Committee
      • Board
      • CEO and Management
      • Auditors
      • Certified Adviser
  • Home
  • About us
    • Our Business
    • Strategy and business model
    • Management
    • Board of Directors
    • Contact us
  • Pipeline
    • Our Science
    • Pipeline overview
    • Projects
      • Rugocrixan
      • Fosrugocrixan
    • Business Development
    • IP
    • Publications
  • Therapeutic areas
    • Myocardial infarction
    • Ovarian cancer
  • Investors
    • Presentations
    • Press Releases
    • Financial Reports
    • Financial Calendar
    • Events
    • The Share
    • Sustainability
    • Corporate Governance
      • Articles of Association
      • Annual General Meeting
      • Board Committee
      • Board
      • CEO and Management
      • Auditors
      • Certified Adviser
  • Svenska
Start>News>Report>Interim>Q3

Q3

  • Interim Report Third Quarter 2024, July 1 – September 30 Kancera AB (publ.), org.no. 556806-8851

    15 November 2024

  • Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851

    17 November 2023

  • Interim report third quarter, January 1 – September 30, 2022, Kancera ab (publ.), org.nr. 556806-8851

    27 October 2022

  • Interim report for third quarter 2021,1 January – 30 September 2021 Kancera AB (publ.), org.nr. 556806-8851

    19 November 2021

  • Interim report for the third quarter 2020, January 1st – September 30th, 2020

    20 November 2020

  • Interim report for the third quarter 2019, 1 January – 30 September 2019

    26 November 2019

  • INTERIM REPORT FOR KANCERA  AB (publ) 1st January – 30th September 2018

    23 November 2018

  • INTERIM REPORT FOR KANCERA  AB (publ) 1st January – 30th September 2017

    17 November 2017

  • Interim Report for Kancera AB (publ) Q3 2016, January 1 – September 30, 2016

    18 November 2016

  • Interim Report for Kancera AB (publ) Q3 2015. January 1 – September 30, 2015.

    20 November 2015

+46 (0)8 5012 60 80Nanna Svarts väg 4, 171 65 Solna, Sweden

Content

  • Home
  • About us
  • Pipeline
  • Therapeutic areas
  • Investors

Shortcuts

  • Press Releases
  • Financial Reports
  • Financial Calendar
  • Website Policy

Copyright © 2025 Novakand AB. All Rights Reserved. Design by Clavis Communications